Clofarabine in the Treatment of Elderly Patients with Acute Myeloid Leukemia

Aleem, Aamer; Anjum, Farhan; Algahtani, Farjah; Iqbal, Zafar; Alsaleh, Khalid; AlMomen, Abdulkareem

추천

검색

자료유형: 학술저널

저자정보: Aleem, Aamer (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) Anjum, Farhan (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) Algahtani, Farjah (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) Iqbal, Zafar (Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences) Alsaleh, Khalid (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) AlMomen, Abdulkareem (Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제2호

발행연도: 2013.1

수록면: 1,089 - 1,092 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Elderly patients with acute myeloid leukemia (AML) have a poor outcome because of co-morbidities, poor tolerance to intensive chemotherapy and inherently more resistant disease. Clofarabine is a second generation nucleoside analogue which has shown promising activity in elderly patients with AML. This study was conducted to review the outcome of treatment with clofarabine in a group of such patients. Methods: The records of 5 elderly patients who were diagnosed to have AML and treated with clofarabine over a 12 month period were reviewed retrospectively. Results: There were 2 female and 3 male patients with a median age of 68 years (range 65-82). At the time of treatment, 2 patients had newly diagnosed AML not considered suitable for intensive therapy, while 3 patients had partial or no response to conventional chemotherapy. The overall response rate was 100%, all patients achieving a complete remission. Induction and consolidation were well tolerated. All patients developed neutropenia with a median duration of 20 days (range 17-42). One patient developed hand and foot syndrome and a generalized rash but recovered. There was no mortality and all patients remained in remission after a median follow-up of 5.2 months (Range 3-10). Conclusion: Clofarabine (alone or in combination) is active in elderly AML patients with an acceptable safety profile and should be considered a potential option in this group.

#Acute myeloid leukemia #clofarabine #elderly

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Aleem, Aamer

소속기관 Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid Univers